NEURONTIN 300 MG
GABAPENTIN : 300 MG · DIN 02084279 · BGP PHARMA ULC
Health Canada status: MARKETED
What is NEURONTIN?
NEURONTIN 300 MG contains GABAPENTIN : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02084279, held by BGP PHARMA ULC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 05-May-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NEURONTIN used for?
NEURONTIN (gabapentin) is indicated as adjunctive therapy for the management of patients with epilepsy who are not satisfactorily controlled with conventional therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is NEURONTIN called?
The same molecule, GABAPENTIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Gabapentin Teva | Latin | Czechia, Iceland, Norway |
| GAPENTIN | Latin | Australia, Saudi Arabia |
| APX-Gabapentin | Latin | Australia |
| Gabacor | Latin | Australia |
| GABANOX | Latin | Czechia |
| GRIMODIN | Latin | Czechia |
| Gabapentin Sandoz | Latin | Australia, Iceland |
| GASENLAN | Latin | Czechia |
| GABAPENTIN-WGR | Latin | Australia |
| GABAGAMMA | Latin | Czechia |
| Gabapentin APOTEX | Latin | Australia |
| GORDIUS | Latin | Czechia |
| Gabagen | Latin | Iceland |
| Gabanet | Latin | Saudi Arabia |
| Gabapenstad | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02084279 |
|---|---|
| Brand name | NEURONTIN |
| Generic / active ingredient | GABAPENTIN : 300 MG |
| Manufacturer | BGP PHARMA ULC |
| Strength | 300 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N02BF01 GABAPENTIN |
| AHFS class | 28:12.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 05-May-2023 |
| Original market date | 1994-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02084279 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2084279 |
| Brand name | NEURONTIN |
| Active ingredient / INN | GABAPENTIN : 300 MG |
| ATC code | N02BF01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02 |
| AHFS class | 28:12.92 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | BGP PHARMA ULC |
How is it stored and handled?
null
How is it supplied?
Capsules: bottles of 100 capsules (100 mg, 300 mg, 400 mg). Tablets: bottles of 100 tablets (600 mg, 800 mg).
Which pack is which?
| Strength on the label | 300 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Packaging as described in the monograph | Capsules: bottles of 100 capsules (100 mg, 300 mg, 400 mg). Tablets: bottles of 100 tablets (600 mg, 800 mg). |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Is GABAPENTIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02BF01 GABAPENTIN. 60 of 161 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-GABAPENTIN | 100 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02244304 |
| APO-GABAPENTIN | 300 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02244305 |
| APO-GABAPENTIN | 400 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02244306 |
| APO-GABAPENTIN | 600 MG | TABLET | APOTEX INC | MARKETED | DIN 02293358 |
| APO-GABAPENTIN | 800 MG | TABLET | APOTEX INC | MARKETED | DIN 02293366 |
| AURO-GABAPENTIN | 100 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02321203 |
| AURO-GABAPENTIN | 300 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02321211 |
| AURO-GABAPENTIN | 400 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02321238 |
| AURO-GABAPENTIN TABLETS | 600 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02428334 |
| AURO-GABAPENTIN TABLETS | 800 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02428342 |
Who else supplies GABAPENTIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GABAPENTIN appears in 555 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does GABAPENTIN cost around the world?
GABAPENTIN is listed on 16 national price registers Nexara tracks, across 587 pack listings published on 14 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 6 | 261 | 03 Sep 2026 |
| Australia | ex-manufacturer | 13 | 54 | 08 Sep 2026 |
| Italy | prezzo al pubblico (classe A) | 6 | 46 | 02 Sep 2026 |
| Czechia | max producer price (ex-factory) | 7 | 45 | 03 Sep 2026 |
| Saudi Arabia | public | 19 | 33 | 01 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 25 | 27 | 03 Sep 2026 |
| South Africa | single exit price | 26 | 26 | 01 Sep 2026 |
| Hungary | producer price (ex-factory) | 13 | 18 | 03 Sep 2026 |
| Iceland | max wholesale | 7 | 16 | 02 Sep 2026 |
| Romania | max producer price | 15 | 15 | 03 Sep 2026 |
| Norway | max AUP (pharmacy retail) | 4 | 14 | 07 Sep 2026 |
| Greece | producer price (ex-factory) | 9 | 9 | 03 Sep 2026 |
| United Arab Emirates | public | 8 | 8 | 31 Aug 2026 |
| United Kingdom | hospital | 6 | 6 | 31 Aug 2026 |
| Luxembourg | reimbursement | 5 | 5 | 05 Sep 2026 |
| Bahrain | retail (max) | 3 | 4 | 01 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.